@article{fdi:010065442,
  title = {{R}esistance detected by pyrosequencing following zidovudine monotherapy for prevention of {HIV}-1 mother-to-child-transmission},
  author = {{O}lson, {S}. {C}. and {N}go-{G}iang-{H}uong, {N}icole and {B}eck, {I}. and {D}eng, {W}. {J}. and {B}ritto, {P}. and {S}hapiro, {D}. {E}. and {B}umgarner, {R}. {E}. and {M}ullins, {J}. {I}. and {V}an {D}yke, {R}. {B}. and {J}ourdain, {G}onzague and {F}renkel, {L}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}o prevent mother-to-child-transmission of {HIV}-1, the 2010 {WHO} guidelines recommended prenatal zidovudine ({ZDV}) monotherapy (option {A}). {T}o determine if {ZDV} monotherapy selects for {HIV} resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. {ZDV}-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). {T}hese data raise the question whether women administered {ZDV} monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.},
  keywords = {{HIV}-1 ; mother-to-child-transmission ; prophylaxis ; pyrosequencing ; resistance ; zidovudine ; {THAILANDE}},
  booktitle = {},
  journal = {{A}ids},
  volume = {29},
  numero = {12},
  pages = {1467--1471},
  ISSN = {0269-9370},
  year = {2015},
  DOI = {10.1097/qad.0000000000000737},
  URL = {https://www.documentation.ird.fr/hor/fdi:010065442},
}